| Drug Name |
Verteporfin |
| Drug ID |
BADD_D02352 |
| Description |
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. |
| Indications and Usage |
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors. |
| Marketing Status |
approved; investigational |
| ATC Code |
S01LA01 |
| DrugBank ID |
DB00460
|
| KEGG ID |
D01162
|
| MeSH ID |
D000077362
|
| PubChem ID |
11980904
|
| TTD Drug ID |
D0I3XG
|
| NDC Product Code |
Not Available |
| UNII |
0X9PA28K43
|
| Synonyms |
Verteporfin | BPD-MA | Benzoporphyrin Derivative Monoacid Ring A | Verteporphin | 18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester | BPD Verteporfin | Visudyne |
